Latest Insulin degrading enzyme Stories

Funds to Advance Research Across Key Tau Programs in Alzheimer's disease NEW YORK, May 22, 2013 /PRNewswire/ -- Oligomerix, Inc., a privately held company pioneering the development of disease modifying therapeutics for Alzheimer's disease (AD) and related neurodegenerative disorders, announced today the completion of its Series B financing, which includes both issuance of new convertible preferred shares and warrants that would represent approximately $2.8M in new investments in...

Scientists’ picture of how a gene strongly linked to Alzheimer’s disease harms the brain may have to be revised, researchers at Washington University School of Medicine in St. Louis have found. People with harmful forms of the APOE gene have up to 12 times the risk of developing Alzheimer’s disease compared with those who have other variations of the gene. Many researchers believe that the memory loss and cognitive problems of Alzheimer’s result from the buildup over many years...

Brett Smith for redOrbit.com - Your Universe Online Researchers from Australia’s Commonwealth Scientific and Industrial Research Organisation (CSIRO) are reporting significant progress in developing a blood test that can predict the onset of Alzheimer’s in an individual. According to their report in the journal Molecular Psychiatry, the researchers said they have identified several biomarkers that are associated with the toxic build-up of beta amyloid, a brain signaling protein....

innerQuest Psychiatry is a psychiatrist & psychologist group in Asheville, NC composed of Dr. Leonard Cruz, Dr. Steven Buser and Dr. Richard Smoot. In this article, Dr. Cruz reviews recent evidence of a cancer drug showing hopeful signs for new treatment in Alzheimers disease. Asheville, NC (PRWEB) December 01, 2012 innerQuest Psychiatry is a psychiatrist & psychologist group in Asheville, NC composed of Dr. Leonard Cruz, Dr. Steven Buser and Dr. Richard Smoot. In this article,...

A link has been discovered between Alzheimer’s disease and the activity level of a protein called eIF2alpha. This has been reported in a new study conducted at the University of Haifa’s Sagol Department of Neurobiology, recently published in the journal Neurobiology of Aging. According to Prof. Kobi Rosenblum, head of the Department, altering the performance of this protein via drug therapy could constitute a treatment for Alzheimer’s, which is incurable. Alzheimer’s research in...

Connie K. Ho for redOrbit.com – Your Universe Online Getting the right amount of sleep is more important than ever, as sleep is thought to have important health effects for individuals. In particular, a study by researchers at Washington University School of Medicine in St. Louis involving laboratory mice found that sleep disruption could be an early sign of Alzheimer’s disease. In the project, the scientists worked with a mouse model and discovered that the first indicators of...

Alzheimer's disease (AD) is a devastating neurodegenerative disorder that causes progressive cognitive impairment and memory loss. Now, a new study published by Cell Press in the September 8 issue of the journal Neuron identifies a previously unrecognized link between neuroinflammation and the classical pathological brain changes that are the hallmark of the disease. In addition, the research identifies a new potential therapeutic target for AD. AD is characterized by abnormal accumulation...

Taking a new approach to the treatment and prevention of Alzheimer's disease, a research team led by investigators at the Mayo Clinic campus in Florida has shown that druglike compounds can speed up destruction of the amyloid beta (A-beta) proteins that form plaque in the brains of patients with the disorder.Researchers say their study, published in the April 22 online issue of PLoS ONE, demonstrates that this strategy is a viable and exciting alternative to the approach most drug designers...